Right ventricular involvement in cancer therapy–related cardiotoxicity: the emerging role of strain echocardiography

Evaluating Right Ventricular Function To Reveal Cancer Therapy Cardiotoxicity

“…The newest reviews highlighted the expediency of using recently developed imaging techniques, such as 3D echocardiography and speckle tracking analysis in diagnosing RV dysfunction. The combined results obtained via various echocardiographic methods allow obtaining a deeper understanding of the RV pathology, which, in our opinion, would lead to a more accurate diagnosis and better clinical management of patients with cardiovascular diseases in general [10], as well as during their anticancer therapy [14].…”

“…A recently published review [14] was devoted to studies on using the RV myocardial deformation to detect cancer therapy cardiotoxicity. It included the data from eight research projects undertaken in 2015-2019.…”

Oncocardiology: new challenges, new opportunities

“…While a robust body of evidence covering LV function during cancer therapy is available, the characteristics and clinical relevance of right ventricular (RV) impairment are poorly understood. Right ventricular dysfunction upon cancer therapy is more common in cancer survivors than LV dysfunction and develops 6-7.5 months after exposure to anthracyclines and/or trastuzumab with a dose-dependent incidence [31]. Threedimensional assessment of RV volumes including the assessment of RV strain may represent a beneficial tool for the evaluation of chemotherapy-related RV dysfunction and has yielded consistent results, but it is not yet broadly applied in standardized echocardiographic examinations [32].…”

“…Threedimensional assessment of RV volumes including the assessment of RV strain may represent a beneficial tool for the evaluation of chemotherapy-related RV dysfunction and has yielded consistent results, but it is not yet broadly applied in standardized echocardiographic examinations [32]. Future studies are needed to determine appropriate cutoff values and recommendations for the use in oncocardiology [31].…”

Cardiotoxicity of anthracycline‑free targeted oncological therapies in HER2‑positive breast cancer (Review)

“…Based on previous studies, it is speculated that the right heart is more sensitive to chemotherapy because its structure is thinner than that of the left heart and contains fewer myofibrils (52); therefore, its assessment may predict cardiac dysfunction that has not yet occurred in the left ventricle. For the measurement of right heart function, the guidelines from the British Society of Echocardiography are recommended; the main measurement indicators include RV ejection fraction, RV fractional area change, tricuspid annular plane systolic excursion, and RV longitudinal strain (53,54). However, further large scale studies are required to determine the significance of RV function monitoring in the prediction and prognosis of heart function in patients with breast cancer after treatment.…”